ABVC BioPharma, Inc.
Key statistics
from XBRL data in SEC filingsAI briefing
from the latest 10-K, 10-Q and 8-K eventsABVC BioPharma is a clinical-stage botanical drug and medical device developer that has shifted toward licensing its pipeline to subsidiaries and related parties while accumulating Taiwan land assets.
What they do
ABVC develops plant-derived new drugs and medical devices, in-licensing candidates from Asia-Pacific research institutions and running proof-of-concept trials through Phase II. Trials cited in the 10-K include ABV-1701 (Vitargus) for vitrectomy surgery in Australia and Thailand, ABV-1505 for adult ADHD at UCSF, ABV-1601 for major depression in cancer patients at Cedars Sinai, and ABV-1519 for EGFR wild-type NSCLC. Its California subsidiary BioKey provides contract development and manufacturing services including formulation development, analytical methods, stability studies, and clinical trial material manufacturing. The company also holds land in Taiwan through subsidiaries and related parties.
Revenue drivers
- Contract development and manufacturing (BioKey) — BioKey provides CDMO services such as API characterization, formulation development, analytical method development, stability studies, and Phase I-III clinical trial material manufacturing.
- Intellectual property out-licensing — ABVC has licensed core programs to a subsidiary and related parties (CNS pipeline to AiBtl, oncology to OncoX, ophthalmology to ForSeeCon) and retains licensing economics; no payment from prior-year out-licensing receivables was collected in 2025.
- Product sales and grants — Reported annual revenue has been small and volatile, ranging from $152,430 in 2023 to $969,783 in 2022 and $296,000 in 2025; the quarterly spike of $795,950 in 2025-09-30 shows no stable recurring base.
Recent performance
Annual revenue was $296,000 in 2025, down from $509,589 in 2024 and $969,783 in 2022. Net loss was $7.9 million in 2025 versus $4.9 million in 2024, and operating cash flow was negative $3.0 million for 2025. The company reported total assets of $21.06 million at December 31, 2025, up 179% from $7,539,907 in 2024, driven mainly by net property and equipment of $12,835,409, up from $511,088. At June 30, 2026, the latest balance sheet shows total assets of $19.4 million, total liabilities of $7.1 million, shareholder equity of $10.3 million, and cash and equivalents of only $31,944.
Strategy
Management describes a shift from a purely IP-driven biotech to a hybrid asset model combining intellectual property, licensing revenue potential, equity in development subsidiaries, and tangible land assets. It licensed CNS, oncology, and ophthalmology programs to AiBtl, OncoX, and ForSeeCon, stating this transfers development risk while retaining licensing economics and equity participation. It is accumulating Taiwan land: a 5,995.41 square meter Longtan District property valued at $4.6 million as of December 31, 2025, and 69,230.90 square meters in Puli Township appraised at about $8.0 million as of January 30, 2026. The Puli plan is a staged medicinal plant cultivation and processing platform, with projected annual output value of roughly $60,000 to $360,000. The company also acquired 20% of a Zhonghui property in Chengdu, China for 370,000 shares, with certification still pending Chinese government approval.
Risks
- Minimal revenue and recurring losses — Revenue fell to $296,000 in 2025 with a $7.9 million net loss and negative $3.0 million operating cash flow.
- Very low cash balance — Cash and equivalents were $31,944 at June 30, 2026 against $7.1 million of liabilities, making the company dependent on external financing.
- Clinical and partner dependence — Pipeline candidates are largely Phase I/II and the 10-K states the company would seek a large pharmaceutical partner after Phase II to fund Phase III, file the NDA, and commercialize.
- Land title and related-party structuring — Taiwan land is registered under a related-party landholder or pending government title transfer review, and the China property certification is still awaiting approval.
Outlook
Management describes 2025 as a structural strengthening of the balance sheet and says it will continue a land-first, development-later approach that preserves strategic optionality in Asia. The Puli site is characterized as a scalable, phased, multi-year development platform rather than a near-term construction project. The company states the licensing model has separated development risk from long-term value participation and expects it to continue to benefit ABVC, though it collected no out-licensing payments in 2025.